MA26431A1 - Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b - Google Patents
Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2bInfo
- Publication number
- MA26431A1 MA26431A1 MA24630A MA24630A MA26431A1 MA 26431 A1 MA26431 A1 MA 26431A1 MA 24630 A MA24630 A MA 24630A MA 24630 A MA24630 A MA 24630A MA 26431 A1 MA26431 A1 MA 26431A1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- treatment
- mamifer
- arylpyrimidines
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1821896P | 1996-05-23 | 1996-05-23 | |
US4037797P | 1997-03-10 | 1997-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26431A1 true MA26431A1 (fr) | 2004-12-20 |
Family
ID=26690869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA24630A MA26431A1 (fr) | 1996-05-23 | 1997-05-21 | Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b |
Country Status (32)
Country | Link |
---|---|
US (1) | US5863924A (fr) |
EP (1) | EP0901474B1 (fr) |
JP (1) | JP2001525794A (fr) |
KR (1) | KR100518101B1 (fr) |
CN (1) | CN1109675C (fr) |
AR (1) | AR007253A1 (fr) |
AT (1) | ATE323682T1 (fr) |
AU (1) | AU725891B2 (fr) |
BR (1) | BR9709599A (fr) |
CA (1) | CA2255705A1 (fr) |
CO (1) | CO4950514A1 (fr) |
CZ (1) | CZ291849B6 (fr) |
DE (1) | DE69735712T2 (fr) |
DK (1) | DK0901474T3 (fr) |
ES (1) | ES2262178T3 (fr) |
HK (1) | HK1020345A1 (fr) |
HR (1) | HRP970275B1 (fr) |
HU (1) | HUP9901535A3 (fr) |
ID (1) | ID16969A (fr) |
IL (1) | IL127056A (fr) |
MA (1) | MA26431A1 (fr) |
MY (1) | MY119181A (fr) |
NO (1) | NO311800B1 (fr) |
NZ (1) | NZ332802A (fr) |
PT (1) | PT901474E (fr) |
RU (1) | RU2189976C2 (fr) |
SA (2) | SA05260356B1 (fr) |
TR (1) | TR199802391T2 (fr) |
TW (1) | TW440563B (fr) |
UY (1) | UY24560A1 (fr) |
WO (1) | WO1997044326A1 (fr) |
YU (1) | YU53298A (fr) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1012151B1 (fr) * | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Pyridines a cycle fusionne et a substitution heterocyclyle, antagonistes du facteur de liberation de la cortitropine (crf), utiles dans le traitement des troubles lies au snc et au stress |
US6040315A (en) * | 1997-10-30 | 2000-03-21 | Day; Charles E. | Antacid co-polymer of guanidine and polyethylenimine |
DE19844291A1 (de) * | 1998-09-18 | 2000-03-23 | Schering Ag | Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
EP1144390A2 (fr) * | 1999-01-22 | 2001-10-17 | Amgen Inc., | Inhibiteurs de kinase |
EP1057831B1 (fr) * | 1999-05-26 | 2004-09-22 | F. Hoffmann-La Roche Ag | Procédé de fabrication de dérivés de type vinylpyrimidine |
ATE250417T1 (de) * | 1999-07-30 | 2003-10-15 | Pharmagene Lab Ltd | Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
PL355639A1 (en) | 1999-09-10 | 2004-05-04 | Merck & Co, Inc. | Tyrosine kinase inhibitors |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
BR0108611A (pt) * | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6444477B1 (en) | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
YU90503A (sh) * | 2001-05-14 | 2006-03-03 | Bristol-Myers Squibb Pharma Company | Supstituisani pirazinoni, piridini i pirimidini kao faktor oslobađanja kortikotropina |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
JP2005500294A (ja) * | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
CA2450562A1 (fr) | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de tyrosine kinase |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
CN1633293A (zh) * | 2002-02-13 | 2005-06-29 | 药物基因实验室有限公司 | 5-ht2b受体拮抗剂 |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (fr) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | Derives de la pyrimidine substituee par 4-imidazolyle presentant une activite d'inhibition de cdk |
US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
US20040023981A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
AP2385A (en) * | 2002-12-20 | 2012-03-23 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
JP2006528617A (ja) * | 2003-07-24 | 2006-12-21 | ファーマジーン ラボラトリーズ リミテッド | 5−ht2b受容体アンタゴニスト |
CN100441228C (zh) * | 2003-07-25 | 2008-12-10 | 西巴特殊化学制品控股公司 | 取代的2,4-双(烷基氨基)嘧啶或-喹唑啉作为抗菌剂的用途 |
DK1656372T3 (da) | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme |
US20070099938A1 (en) * | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
WO2005079845A1 (fr) | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | Agents de prévention pour la migraine |
ATE485824T1 (de) * | 2004-04-13 | 2010-11-15 | Icagen Inc | Polycyclische pyrimidine als kaliumionenkanal- modulatoren |
MXPA06013165A (es) * | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
EP1751142A1 (fr) * | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Derives pyrimidiques pour le traitement de la croissance de cellules anormales |
CA2566477A1 (fr) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Derives de pyrimidine destines au traitement de croissance cellulaire anormale |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1796673A2 (fr) * | 2004-09-23 | 2007-06-20 | Reddy US Therapeutics, Inc. | Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant |
ES2380550T3 (es) | 2004-11-24 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Compuestos de espiro-2,4-pirimidindiamina y sus usos |
GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
CN101151249B (zh) * | 2005-03-31 | 2011-04-06 | 辉瑞产品公司 | 环戊吡啶及四氢喹啉衍生物 |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
EP1890703B1 (fr) * | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Composes pyrimidine en tant qu'inhibiteurs des recepteurs chemokine |
US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
US20080293942A1 (en) * | 2005-11-28 | 2008-11-27 | Cousins Russell D | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives |
US8222274B2 (en) | 2006-02-20 | 2012-07-17 | Astellas Pharma Inc. | Pyrrole derivative or salt thereof |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
WO2008079918A1 (fr) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Dérivés d'indol-4-yl-pyrimidinyl-2-yl-amine et leur utilisation comme inhibiteurs de la kinase dépendante des cyclines |
AU2008220009A1 (en) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | Macrocyclic compound |
DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
WO2009026276A1 (fr) * | 2007-08-22 | 2009-02-26 | Irm Llc | Composés et compositions de 5- (4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases |
RU2378278C2 (ru) * | 2008-01-24 | 2010-01-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ |
CA2715192A1 (fr) | 2008-02-19 | 2009-08-27 | Adolor Corporation | Beloxepine, ses enantiomeres et certains de leurs analogues convenant au traitement de la douleur |
DK2268635T3 (en) | 2008-04-21 | 2015-09-14 | Taigen Biotechnology Co Ltd | Heterocyclic Compounds |
NZ596123A (en) * | 2009-05-19 | 2014-08-29 | Dow Agrosciences Llc | Compounds and methods for controlling fungi |
KR20130005263A (ko) | 2009-12-30 | 2013-01-15 | 아르퀼 인코포레이티드 | 치환된 나프탈레닐-피리미딘 화합물 |
CN102786512A (zh) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
CA2952230C (fr) | 2014-06-13 | 2023-03-21 | Yuma Therapeutics, Inc. | Composes pyrimidiques et procedes les utilisant |
CN104725322B (zh) * | 2015-02-16 | 2017-05-24 | 同济大学 | 一种2‑胺基嘧啶类化合物及其制备方法 |
WO2016173438A1 (fr) * | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | Composé aryl-pyrimidine tricyclique ou à cycle fusionné utilisé comme inhibiteur de kinase |
RU2605265C1 (ru) * | 2015-10-06 | 2016-12-20 | федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) | Анальгезирующее и противовоспалительное средство на основе 5-бутил-6-гидрокси-2-метилпиримидин-4(3h)-она |
US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
AU2018352695A1 (en) | 2017-10-19 | 2020-05-28 | Effector Therapeutics, Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
CN108904503B (zh) * | 2018-07-02 | 2021-09-28 | 陕西科技大学 | 6-氯-5-硝基-2,4-二氨基嘧啶在治疗慢性粒细胞白血病药物中的应用 |
AR122450A1 (es) | 2020-05-08 | 2022-09-14 | Lilly Co Eli | Compuestos de (trifluorometil)pirimidin-2-amina |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3535330A (en) * | 1968-04-29 | 1970-10-20 | Sandoz Ag | 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof |
US3965101A (en) * | 1973-07-26 | 1976-06-22 | E. R. Squibb & Sons, Inc. | 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines |
DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4543248A (en) * | 1979-03-19 | 1985-09-24 | The Upjohn Company | Method for immunoregulation with 6-aryl pyrimidine compounds |
US5002951A (en) * | 1979-03-19 | 1991-03-26 | The Upjohn Company | Method for treating bacterial and protozoal infections |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
AU531507B2 (en) * | 1979-08-08 | 1983-08-25 | G.D. Searle & Co. | 8-substituted 7-phenyl-1,2,4-triazolo(4,3-c) pyrimidines -5-amines and amides |
US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
FR2539741A1 (fr) * | 1983-01-21 | 1984-07-27 | Sanofi Sa | Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent |
US4512993A (en) * | 1983-07-25 | 1985-04-23 | Sterling Drug Inc. | 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof |
US4504482A (en) * | 1983-07-28 | 1985-03-12 | Sterling Drug Inc. | [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof |
EP0210228A1 (fr) * | 1985-02-05 | 1987-02-04 | The Upjohn Company | Composes de 4-substitue-6-aryl-pyrimidine |
US4711888A (en) * | 1985-07-24 | 1987-12-08 | Pfizer Inc. | Hydroxy and alkoxy pyrimidines |
US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
WO1989011279A1 (fr) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Compose heteropolycyclique non fusionne ayant une interaction avec des acides nucleiques |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
IE63502B1 (en) * | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
GB9012311D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
US5698444A (en) * | 1993-12-23 | 1997-12-16 | Eli Lilly And Company | Serotonin receptor protein and related nucleic acid compounds |
US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
JP3145410B2 (ja) * | 1995-04-13 | 2001-03-12 | 大鵬薬品工業株式会社 | 新規な4,6−ジアリールピリミジン誘導体及びその塩 |
US5795905A (en) * | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
-
1997
- 1997-05-09 TW TW086106209A patent/TW440563B/zh not_active IP Right Cessation
- 1997-05-14 BR BR9709599A patent/BR9709599A/pt not_active Application Discontinuation
- 1997-05-14 JP JP54148297A patent/JP2001525794A/ja not_active Ceased
- 1997-05-14 AT AT97923071T patent/ATE323682T1/de not_active IP Right Cessation
- 1997-05-14 CZ CZ19983803A patent/CZ291849B6/cs not_active IP Right Cessation
- 1997-05-14 ES ES97923071T patent/ES2262178T3/es not_active Expired - Lifetime
- 1997-05-14 KR KR10-1998-0709451A patent/KR100518101B1/ko not_active IP Right Cessation
- 1997-05-14 IL IL12705697A patent/IL127056A/xx not_active IP Right Cessation
- 1997-05-14 WO PCT/EP1997/002454 patent/WO1997044326A1/fr active IP Right Grant
- 1997-05-14 HU HU9901535A patent/HUP9901535A3/hu unknown
- 1997-05-14 CN CN97196018A patent/CN1109675C/zh not_active Expired - Fee Related
- 1997-05-14 PT PT97923071T patent/PT901474E/pt unknown
- 1997-05-14 DE DE69735712T patent/DE69735712T2/de not_active Expired - Fee Related
- 1997-05-14 CA CA002255705A patent/CA2255705A1/fr not_active Abandoned
- 1997-05-14 EP EP97923071A patent/EP0901474B1/fr not_active Expired - Lifetime
- 1997-05-14 AU AU28978/97A patent/AU725891B2/en not_active Ceased
- 1997-05-14 NZ NZ332802A patent/NZ332802A/xx unknown
- 1997-05-14 TR TR1998/02391T patent/TR199802391T2/xx unknown
- 1997-05-14 DK DK97923071T patent/DK0901474T3/da active
- 1997-05-14 RU RU98123001/04A patent/RU2189976C2/ru not_active IP Right Cessation
- 1997-05-20 US US08/858,964 patent/US5863924A/en not_active Expired - Fee Related
- 1997-05-20 MY MYPI97002204A patent/MY119181A/en unknown
- 1997-05-20 HR HR970275A patent/HRP970275B1/xx not_active IP Right Cessation
- 1997-05-21 MA MA24630A patent/MA26431A1/fr unknown
- 1997-05-22 CO CO97028097A patent/CO4950514A1/es unknown
- 1997-05-22 AR ARP970102176A patent/AR007253A1/es unknown
- 1997-05-22 UY UY24560A patent/UY24560A1/es not_active IP Right Cessation
- 1997-05-23 ID IDP971727A patent/ID16969A/id unknown
- 1997-07-01 SA SA05260356A patent/SA05260356B1/ar unknown
- 1997-07-01 SA SA97180191A patent/SA97180191B1/ar unknown
-
1998
- 1998-11-19 NO NO19985392A patent/NO311800B1/no not_active Application Discontinuation
- 1998-11-23 YU YU53298A patent/YU53298A/sr unknown
-
1999
- 1999-11-29 HK HK99105532A patent/HK1020345A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26431A1 (fr) | Procede pour la preparation des arylpyrimidines, leur utilisation pour preparer des medicaments et pour traiter un mamifere dont l'etat pathologique peut etre attenue par traitement avec antagoniste du 5ht2b | |
HUP9903654A3 (en) | Biconvex rapidly disintegrating dosage forms | |
TR199501517A2 (tr) | Yeni antitrombotik formül, bunun imal edilmesi icin proses, ve bunun kullanilmasi. | |
EP0749302A4 (fr) | Derives de l'acide hydroxamique et de l'acide carboxylique, leur mode de preparation et d'utilisation | |
HK1000781A1 (en) | Apparatus and process to ascertain an action, and use of the apparatus and the process | |
FR2732680B1 (fr) | Composes de type ceramides, leur procede de preparation et leur utilisation | |
FR2660556B1 (fr) | Microspheres, leur procede de preparation et leur utilisation. | |
FR2772617B1 (fr) | Comprime de progesterone et son procede de preparation | |
IT7928062A0 (it) | 4(3h)-chinazolinoni sostituiti nella meta' 3-aromatica, procedimento per la loro produzione e loro impiego. | |
MA23309A1 (fr) | Procede de preparation de nouveaux composes. | |
FR2668389B1 (fr) | Procede de traitement antipollution d'un catalyseur de raffinage a l'etat use et recuperation des metaux. | |
DE69203755T2 (de) | Kernbrennstofftabletten und Verfahren zur Herstellung derselben. | |
FR2668031B1 (fr) | Bouillies bordelaises et leur procede de preparation. | |
FR2682371B1 (fr) | Phyllosilicates 2:1 trioctaedriques et leur procede de preparation. | |
DK558083A (da) | Somatostatinforbindelse, fremgangsmaade til fremstilling deraf samt mellemprodukt til brug ved udoevelse af fremgangsmaaden | |
DZ2077A1 (fr) | Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites. | |
FR2725450B1 (fr) | Aminoplastes, procede pour leur preparation et leur utilisation | |
FR2679229B1 (fr) | Procede de preparation du cis-inositol, du meso-inositol, de l'epi-inositol et/ou du cis-quercitol eventuellement deuteres. | |
MA21770A1 (fr) | Peptides sdk ainsi que leur procede de preparation . | |
DE3262930D1 (en) | Compounds of 3-phenoxybenzyl, process for the preparation thereof and their use in the synthesis of biocidal compounds | |
ZA9710972B (en) | Steroid esters, process for their production and their pharmaceutical use. | |
FR2696171B1 (fr) | Procede de preparation du divinylbenzene. | |
FR2683552B1 (fr) | Phyllosilicates 2:1 trioctaedriques non gonflants et leur procede de preparation. | |
DE69105566D1 (de) | Bilderzeugungsverfahren und magnetisches Entwicklungssystem zur Durchführung des Verfahrens. | |
FR2702769B1 (fr) | Nouveau procede de preparation d'alkylpolyosides faiblement colores. |